Dai-ichi Life Insurance Company’s BioMarin Pharmaceuticals BMRN Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,991	Closed	-$1.73M	–	501
2020 Q2	$1.73M	Sell	13,991 -405	-3%	-$40.3K	0.04%	308
2020 Q1	$1.22M	Hold	14,396	–	–	0.05%	332
2019 Q4	$1.22M	Hold	14,396	–	–	0.03%	391
2019 Q3	$970K	Hold	14,396	–	–	0.02%	406
2019 Q2	$1.23M	Sell	14,396 -52,252	-78%	-$4.47M	0.03%	384
2019 Q1	$5.92M	Buy	66,648 +15,509	+30%	+$1.44M	0.15%	155
2018 Q4	$4.35M	Sell	51,139 -413	-0.8%	-$39.3K	0.12%	194
2018 Q3	$5M	Buy	51,552 +6,742	+15%	+$673K	0.11%	189
2018 Q2	$4.22M	Buy	44,810 +34,341	+328%	+$3.01M	0.1%	206
2018 Q1	$849K	Hold	10,469	–	–	0.02%	403
2017 Q4	$934K	Sell	10,469 -29,008	-73%	-$2.52M	0.02%	393
2017 Q3	$3.67M	Sell	39,477 -8,154	-17%	-$721K	0.08%	234
2017 Q2	$4.33M	Sell	47,631 -4,668	-9%	-$425K	0.1%	197
2017 Q1	$4.59M	Buy	52,299 +2,780	+6%	+$247K	0.12%	189
2016 Q4	$4.1M	Buy	+49,519	New	+$4.26M	0.12%	196

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dai-ichi Life Insurance Company's BMRN Position: Q3 2020 in Review

Dai-ichi Life Insurance Company sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 13,991 shares — an estimated $1.73M sold.

Dai-ichi Life Insurance Company first reported a position in BMRN in Q4 2016 and held it in 15 quarters. The position peaked at $5.92M in Q1 2019. 497 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Dai-ichi Life Insurance Company reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Dai-ichi Life Insurance Company sold 13,991 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $1.73M.
Dai-ichi Life Insurance Company first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 15 quarters.
Dai-ichi Life Insurance Company's BioMarin Pharmaceuticals position peaked at $5.92M in Q1 2019.
497 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Dai-ichi Life Insurance Company's 13F filing for Q3 2020, filed 12 Nov 2020.